Health & Biotech EZZ launches new products to support digestive health December 13, 2021 Special Report: EZZ is finishing off a successful year with the launch of two new products as it strengthens its… ASX Health Stocks: Arovella and Imugene break away from the pack on major announcements December 13, 2021 The ASX 200 Health Index (XHJ) is trading flat at the time of writing, compared to the broader index which… Dr Boreham’s Crucible: Visoneering’s taking the longview on short-sightedness – and it’s starting to pay off December 12, 2021 The Great Plague of 2020-’21 has done more than worsen the swelling problem of childhood obesity - it’s also hurting… ScoPo’s Powerplays: Neuren breakthrough, M&A deals, and why EBOS ticks ESG boxes December 10, 2021 Healthcare and life sciences expert Scott Power, who has been a senior analyst with Morgans Financial for 25 years, explains… ASX Health Stocks: Aussie biotechs Argenica and Antisense take major steps in the US December 9, 2021 The ASX 200 Health Index (XHJ) is down by 0.20% at the time of writing, compared to the broader index… Wellnex Life signs JV with Australian Dairy to launch A2 infant formula across shelves December 9, 2021 The JV leverages the respective strengths of both companies to drive sales growth. Diversified health and wellness company Wellnex Life… Cannabis play Epsilon boosted by $2.9m fresh capital as it targets profit in 2022 December 9, 2021 Special Report: The $2.9m capital raising has solidified Epsilon’s balance sheet position as it targets positive EBITDA by 2022. HealthKick Podcast: Life sciences expert on local medical innovations, tech leaders and sector opportunities December 9, 2021 Stockhead’s resident health and biotech expert Tim Boreham is putting down the microscope and picking up the microphone for another… Check Up: Neuren close to FDA drug approval and Compumedics fires up Aussie factory for medical wearables December 9, 2021 Neuren plans New Drug Application, and Compumedics targets manufacturing of wearable medical-grade monitoring technology in Australia. Neuren’s stock price doubles on groundbreaking drug trial, CEO says it’s ‘just getting started’ December 8, 2021 Rett Syndrome is a rare genetic neurological disorder that affects the way the brain develops, causing a progressive loss of… Next» « Previous